Trial Search Results

Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy and radiation therapy. It is not yet known whether Manuka honey is more effective than standard care in preventing pain.

PURPOSE: This randomized phase II clinical trial is studying Manuka honey to see how well it works in preventing esophagitis-related pain in patients receiving chemotherapy and radiation therapy for lung cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Radiation Therapy Oncology Group

Collaborator: National Cancer Institute (NCI)


  • Drug: Manuka honey in liquid form
  • Drug: Manuka honey in lozenge form
  • Drug: Standard supportive care


Phase 2



   - Patients being treated with combination chemotherapy (definitive or adjuvant) and
   radiation therapy once daily for small cell or non-small cell lung cancer (primary
   population for the trial)

      - Patients can receive chemoradiotherapy while on a Radiation Therapy Oncology
      Group (RTOG) lung trial or while not being on a clinical trial

      - No patients receiving chemoradiotherapy while enrolled on a single institution
      trial or trials coordinated by other cooperative groups

   - No patients with metastatic disease

   - At least 5 cm of the esophagus must be in the 60 Gy isodose volume in 1.6 to 2.0 Gy


   - Age 18 and up

   - Able to swallow thick liquids prior to treatment

   - Able to speak English or Spanish in order to complete required forms (verbal
   completion is adequate)

   - No patients with poorly controlled diabetes

   - No known hypersensitivity to honey


   - See Disease Characteristics

   - No patients who have received prior chemotherapy or radiation therapy

   - No patients receiving more than once daily treatments

   - Therapeutic use of honey other than the Manuka honey provided for this trial is not
   allowed while patients are on study

   - Patients must also avoid honey-flavored medical products and/or sugary, viscous

   - Amifostine is not permitted

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting